耐性細胞の選択的優位性をターゲットにすることでEGFR抑制に対する肺がん反応の延長

Lisa Brunet^1,2, David Alexandre^1,2, Jiyoung Lee^1,2

¹Univ Rouen Normandie, INSERM NorDiC UMR 1239, Rouen, France.

Nature communications

|August 22, 2025

まとめ

ソラフェニブは,薬剤耐性非小細胞肺がん (NSCLC) に対して,耐性細胞を排除し,敏感細胞を保存します. この組み合わせ治療は腫瘍の成長を遅らせ,免疫反応を高め,治療の有効性を延長します.

科学分野:

腫瘍学
分子生物学
薬理学について

背景:

非小細胞肺がん (NSCLC) は,耐性細胞亜集団による表皮成長因子受容体チロシンキナーゼ阻害剤 (EGFR- TKI) 治療で再発することが多い.
耐性メカニズムの理解は効果的な長期的ながん治療法の開発に不可欠です

研究の目的:

NSCLCにおけるEGFR-TKI耐性を克服するソラフェニブの有効性を調査する.
耐性および敏感なNSCLC細胞にソラフェニブが作用する分子メカニズムを解明する.

主な方法:

DNAバーコードを用いて細胞を追跡した
治療の組み合わせを評価するために,様々な異種移植と異種移植モデルを使用した.
MAPK相互作用キナーゼ (MKNK) と信号変換器および転写3 (STAT3) の活性化を含む分子経路を分析した.

主要な成果:

ソラフェニブはEGFR- TKI耐性NSCLC細胞を選択的に除去し,敏感な細胞は保存しました.
ソラフェニブは複数のEGFR- TKI耐性メカニズムに対して活性を示した.
ソラフェニブとEGFR-TKIの組み合わせは,腫瘍の成長を遅らせ,炎症細胞の増殖を促した.

結論:

ソラフェニブは,耐性細胞の出現を標的として,NSCLCにおけるEGFR- TKIsの有効性を延長することができます.
ソラフェニブのメカニズムは,MKNKとSTAT3のリン酸化を早期に抑制し,その後MCL1とEGFRのダウンレギュレーションを伴う.
EGFR-TKI治療を受けたNSCLC患者の長期的改善には,組み合わせ療法が有望である.

さらに関連する動画

09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

関連する概念動画

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

02:38

Mitogens and the Cell Cycle

6.6K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

6.6K

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...